09:30 AM EST - Oncolytics Biotech Inc : Announced the dosing of the first patient in the new GOBLET study cohort evaluating pelareorep and modified FOLFIRINOX (mFOLFIRINOX) with or without atezolizumab (Tecentriq®) in newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) patients. The co-primary endpoints of the cohort are objective response rate (ORR) and safety. It is supported by the US$5M Pancreatic Cancer Action Network (PanCAN) Therapeutic Accelerator Award, an innovative program established to accelerate the development of new treatments for pancreatic cancer patients. Oncolytics Biotech Inc
shares T.ONC are trading unchanged at $1.39.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONC%3ACA&qmodStoryID=6415728601034664
